Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD
Octapharma USA, Inc. announced the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, ...
BioSpace11d
Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD
Patients with severe VWD are recommended to utilize long-term prophylaxis with VWF concentrate FDA provides wilate ® with up to seven years of market exclusivity for approved prophylaxis indication ...
Le Lézard10d
Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD
Patients with severe VWD are recommended to utilize long-term prophylaxis with VWF concentrate FDA provides wilate ® with up to seven years of market exclusivity for approved prophylaxis ...
BioSpace11d
About Food and Drug Administration (FDA)
Octapharma USA , Inc. announced the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized ...